CEFOTAX HUP
HUPP
Identification
- Active ingredient (INN)
- CEFOTAXIME SODIQUE
- Internal code
- 13 B 014
- Country of Origin
- Algeria
- Pharmaceutical form
- Powder for IV/IM Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1 flacon de poudre et une ampoule de solvant b/10 flacons de poudre
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Cefotaxime is a third-generation cephalosporin antibiotic.
Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria.
In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy.
Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
Indications
Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system.
Also used before an operation to prevent infection after surgery.
Pharmacodynamics
Cefotaxime is a third generation intravenous cephalosporin antibiotic.
It has broad spectrum activity against Gram positive and Gram negative bacteria.
It does not have activity against
Pseudomonas aeruginosa.
Cefotaxime works by inhibiting bacterial cell wall biosynthesis.
A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.
Mechanism of Action
Penicillin-binding protein 1b (Streptococcus pneumoniae (strain ATCC BAA-255 / R6)) Inhibitor Penicillin-binding protein 2a (Streptococcus pneumoniae (strain ATCC BAA-255 / R6)) Inhibitor Penicillin-binding protein 3 (Bacillus subtilis (strain 168)) Inhibitor + 2 more targets.
Absorption
Rapidly absorbed following intramuscular injection.
Metabolism
Approximately 20-36% of an Intravenous administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.
The desacetyl metabolite has been shown to contribute to the bactericidal activity.
Two other urinary metabolites (M2 and M3) account for about 20-25%.
They lack bactericidal activity.
Hover over products below to view reaction partners Cefotaxime Desacetyl-cefotaxime.
Route of Elimination
Approximately 20-36% of an Intravenous administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.
Half-life
Approximately 1 hour.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
Oral rat
LD is over 20,000 mg/kg while intravenous rat LD is over 7,000 mg/kg.